The Food and Drug Administration (FDA) is keeping its safety review of mifepristone—the primary medication used for abortions in the U.S.—rolling well into next year. The agency dropped a legal filing late Wednesday confirming that the process ordered by Health Secretary Robert F. Kennedy Jr. is still underway.
The current landscape
Since its approval in 2000, the FDA has consistently backed mifepristone’s safety and even loosened access, such as removing the in-person dispensing requirement. However, the current administration is under heavy pressure from anti-abortion groups and congressional allies to tighten those rules. The FDA is currently running a "statistical data mining" project through major health databases to hunt for previously unidentified safety concerns.
What happens next?
The FDA expects to finish its safety study by mid-December, with a full report slated for release no later than March 2027. Once that document drops, the agency will decide if new restrictions are warranted. This review stems from a court-ordered update requested during a lawsuit from Louisiana, which argues that mailing the pill hampers state abortion bans.
While the 5th U.S. Circuit Court of Appeals is currently reviewing the state's standing in that case, the Supreme Court has already intervened to block immediate changes to the drug's availability.
Why it matters
The stakes are high. While withdrawing the drug entirely would be a massive, litigious reach, the review could easily result in "death by a thousand cuts" for access. Experts note that officials could pull back on telehealth prescriptions or restrict who is allowed to prescribe the drug, making it significantly harder for patients to get care without traveling. It’s giving bureaucratic stall tactics, and frankly, the vibes are off for everyone involved.
